Anti-RanBP2 antibody (ab112061)
- Datasheet
- References
- Protocols
Overview
-
Product name
Anti-RanBP2 antibody
See all RanBP2 primary antibodies -
Description
Rabbit polyclonal to RanBP2 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide, corresponding to a region within amino acids 1050-1100 of Human RanBP2 (NP_006258.3).
-
Positive control
- HeLa Whole cell lysate.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
Preservative: 0.09% Sodium azide
Constituents: 99% Tris buffered saline, 0.1% BSA -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
ab112061 was affinity purified using an epitope specific to RanBP2 immobilized on solid support. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
Applications
Our Abpromise guarantee covers the use of ab112061 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | 1/2000 - 1/10000. Predicted molecular weight: 358 kDa. | |
| IP | Use at 2-5 µg/mg of lysate. |
Target
-
Function
E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Could also have isomerase or chaperone activity and may bind RNA or DNA. Component of the nuclear export pathway. Specific docking site for the nuclear export factor exportin-1. -
Pathway
Protein modification; protein sumoylation. -
Involvement in disease
Defects in RANBP2 are the cause of susceptibility to encephalopathy acute necrotizing type 1 (ANE1) [MIM:608033]. A rapidly progressive encephalopathy manifesting in susceptibile individuals with seizures and coma. It can occur within days in otherwise healthy children after common viral infections such as influenza and parainfluenza, without evidence of viral infection of the brain or inflammatory cell infiltration. Brain T2-weighted magnetic resonance imaging reveals characteristic symmetric lesions present in the thalami, pons and brainstem. -
Sequence similarities
Contains 1 PPIase cyclophilin-type domain.
Contains 4 RanBD1 domains.
Contains 8 RanBP2-type zinc fingers.
Contains 1 TPR repeat. -
Domain
Contains F-X-F-G repeats. -
Post-translational
modificationsPolyubiquitinated by PARK2, which leads to proteasomal degradation. -
Cellular localization
Nucleus > nuclear pore complex. Cytoplasmic filaments. - Information by UniProt
-
Database links
- Entrez Gene: 5903 Human
- Omim: 601181 Human
- SwissProt: P49792 Human
- Unigene: 199561 Human
- Unigene: 715056 Human
-
Alternative names
- 358 kDa nucleoporin antibody
- ANE1 antibody
- E3 SUMO-protein ligase RanBP2 antibody
see all
Images
-
Western blot - Anti-RanBP2 antibody (ab112061)All lanes : Anti-RanBP2 antibody (ab112061) at 0.04 µg/ml
Lane 1 : Hela whole cell lysate at 50 µg
Lane 2 : Hela whole cell lysate at 15 µg
Lane 3 : Hela whole cell lysate at 5 µg
Developed using the ECL technique.
Predicted band size: 358 kDa
Exposure time: 10 seconds -
Immunoprecipitation - Anti-RanBP2 antibody (ab112061)Detection of RanBP2 by Western Blot of Immunprecipitate.
ab112061 at 0.1µg/ml staining RanBP2 in HeLa whole cell lysate immunoprecipitated using ab112061 at 3µg/mg lysate (1 mg/IP; 20% of IP loaded/lane).
Detection: Chemiluminescence with exposure time of 3 seconds.
Datasheets and documents
References
ab112061 has not yet been referenced specifically in any publications.
